Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
Provided efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to BRVO
Epistemonikos ID: 4ba32309b67de938ce7439513fbd7744cb2cfcd0
First added on: Nov 17, 2022